Insider Selling: Editas Medicine Inc (EDIT) CFO Sells $147,484.05 in Stock
Editas Medicine Inc (NASDAQ:EDIT) CFO Andrew A. F. Hack sold 6,895 shares of the firm’s stock in a transaction dated Monday, February 4th. The shares were sold at an average price of $21.39, for a total value of $147,484.05. Following the completion of the transaction, the chief financial officer now owns 6,895 shares of the company’s stock, valued at approximately $147,484.05. The sale was disclosed in a document filed with the SEC, which is available through this link.
Shares of NASDAQ:EDIT opened at $19.75 on Friday. Editas Medicine Inc has a 52-week low of $17.80 and a 52-week high of $45.02. The stock has a market capitalization of $928.95 million, a P/E ratio of -6.63 and a beta of 2.56. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.14 and a quick ratio of 13.13.
Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Wednesday, November 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.40. Editas Medicine had a negative net margin of 410.68% and a negative return on equity of 53.15%. The business had revenue of $14.52 million during the quarter, compared to the consensus estimate of $9.83 million. During the same period last year, the business posted ($0.64) EPS. Editas Medicine’s revenue was up 131.2% on a year-over-year basis. On average, sell-side analysts expect that Editas Medicine Inc will post -2.18 EPS for the current year.
Several brokerages have recently weighed in on EDIT. Zacks Investment Research cut Editas Medicine from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. BidaskClub upgraded Editas Medicine from a “hold” rating to a “buy” rating in a report on Tuesday, December 4th. ValuEngine cut Editas Medicine from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Cowen restated a “buy” rating on shares of Editas Medicine in a report on Tuesday, January 22nd. Finally, Chardan Capital restated a “buy” rating and issued a $55.00 price objective on shares of Editas Medicine in a report on Tuesday, January 22nd. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $42.50.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2019/02/09/insider-selling-editas-medicine-inc-edit-cfo-sells-147484-05-in-stock.html.
Editas Medicine Company Profile
Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.
Read More: What is insider trading?
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.